Indiana is currently home to 1214 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
Recruiting
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Clinical Trial Site, Carmel, Indiana
Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Register for Updates
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) As a Bridge to Allogeneic Stem Cell Transplant
NCT06197672
Recruiting
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. The study will evaluate safety in this patient population and also the presence of efficacy signal described by elimination of residual disease to qualify patients for stem cell transplant.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/25/2024
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Acute Myeloid Leukemia
Register for Updates
Factors Affecting Sensory and Motor Learning
NCT05374460
Recruiting
How participants perceive the position of their own hand in various contexts will be examined. This will include changing the visual display to suggest the hand is in a slightly different position, and asking participants to indicate where they think it is by pointing with their other hand.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
11/25/2024
Locations: Hannah Block, Bloomington, Indiana
Conditions: Basic Science
Register for Updates
Neural Basis of Sensory and Motor Learning: Functional Connections
NCT05124301
Recruiting
The purpose of this study is to understand how the sensory and motor areas of the brain work together to keep a person's hand movements accurate (sensorimotor learning). The investigators hope this information may be useful one day to improve rehabilitation techniques in patients with brain lesions.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
11/25/2024
Locations: Indiana University Bloomington, Bloomington, Indiana
Conditions: Basic Science
Register for Updates
Neural Basis of Sensory Learning: Brain Regions
NCT05079516
Recruiting
The purpose of this study is to understand how the sensory and motor areas of the brain work together to keep a person's hand movements accurate (sensorimotor learning). The investigators hope this information may be useful one day to improve rehabilitation techniques in patients with brain lesions.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
11/25/2024
Locations: Indiana University Bloomington, Bloomington, Indiana
Conditions: Basic Science
Register for Updates
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
NCT04916210
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Indiana University - Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
NCT04337177
Recruiting
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/24/2024
Locations: Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, Indiana
Conditions: Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Franciscan Health, Indianapolis, Indiana
Conditions: Myocarditis Acute, Cancer
Register for Updates
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: MOC Research, Mishawaka, Indiana
Conditions: Lower Respiratory Tract Illness
Register for Updates
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
NCT02998710
Recruiting
The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices
Gender:
ALL
Ages:
Between 1 year and 65 years
Trial Updated:
11/19/2024
Locations: Travere Investigational Site, Indianapolis, Indiana
Conditions: Homocystinuria Due to CBS Deficiency
Register for Updates
Pompe Pregnancy Sub-Registry
NCT00567073
Recruiting
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standa... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
11/19/2024
Locations: Indianapolis University School of Medicine- Site Number : 840027, Indianapolis, Indiana
Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Register for Updates